Role of vitamin D derivatives in intestinal tissue of patients with inflammatory bowel diseases

Journal of Crohn's and Colitis

Volumn 8, Issue 9, 2014, Pages 1062-1071

  Martinesi, Maria ^a   Ambrosini, Stefano ^a   Treves, Cristina ^a   Zuegel, Ulrich ^b   Steinmeyer, Andreas ^c   Vito, Annese ^d   Milla, Monica ^d   Bonanomi, Andrea G ^d   Stio, Maria ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Clinical Sciences Global Biomarker Global Discovery Bayer Healthcare   (Germany)

^c Medicinal Chemistry Global Drug Discovery Bayer Healthcare   (Germany)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Adhesion molecules; Inflammatory bowel disease; Matrix metalloproteinase; Vitamin D derivatives

Indexed keywords

CALCITRIOL; CELL ADHESION MOLECULE; GELATINASE A; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; STROMELYSIN; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; ZK 191784; VITAMIN D RECEPTOR; 1,25,26-TRIHYDROXYVITAMIN D3; HYDROXYCOLECALCIFEROL; IMMUNOGLOBULIN; MADCAM1 PROTEIN, HUMAN; MUCOPROTEIN; VITAMIN; VITAMIN D;

ADULT; AGED; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; COLON; COLON BIOPSY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ILEUM; INFLAMMATORY BOWEL DISEASE; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN TARGETING; ULCERATIVE COLITIS; CONTROLLED STUDY; CROHN DISEASE; INTESTINAL TISSUE; INTESTINE BIOPSY; PROTEIN EXPRESSION; TERMINAL ILEUM; ANALOGS AND DERIVATIVES; BIOPSY; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; WESTERN BLOTTING;

BIOPSY; BLOTTING, WESTERN; CALCITRIOL; CELLS, CULTURED; HUMANS; HYDROXYCHOLECALCIFEROLS; IMMUNOGLOBULINS; INFLAMMATORY BOWEL DISEASES; INTERCELLULAR ADHESION MOLECULE-1; INTESTINAL MUCOSA; MATRIX METALLOPROTEINASES; MUCOPROTEINS; VITAMIN D; VITAMINS;

EID: 84906789837     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.02.005     Document Type: Article

References (52)

1. van Assche G. Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs 2007, 12:49-59.
2. Peyrin-Biroulet L., Desreumaux P., Sandborn W.J., Colombel J.F. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008, 372:67-81.
3. Stevens C., Walz G., Singaram C., Lipman B., Zanker A., Muggia D., et al. Tumor necrosis factor-alpha, interleukin-1-beta and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992, 37:818-826.
4. MÛzes G., Molnár B., Tulassay Z., Sipos F. Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol 2012, 18:5848-5861.
5. Kovacs E.J., DiPietro L.A. Fibrogenic cytokines and connective tissue production. FASEB J 1994, 8:854-861.
6. Birkedal-Hansen H., Moore W.G., Bodden M.K., Windson L.J., Birkedal-Hansen B., DeCarlo A., et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993, 4:197-250.
7. Pender S.L., Tickle S.P., Docherty A.J., Howie D., Wathen N.C., MacDonald T.T. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997, 158:1582-1590.
8. Murphy G., Reynolds J.J., Royce P.M., Steinmann B. Connective tissue and its heritable disorders: molecular, genetic, and medical aspects. Extracellular matrix degradation 1993, 287-316. Wiley-Liss, Inc., New York. G. Murfy (Ed.).
9. von Lampe B., Barthel B., Coupland S.E., Riecken E.O., Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000, 47:63-73.
10. Leppert D., Hauser S.L., Kishiyama J.L., An S., Zeng L., Goetzl E.J. Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. FASEB J 1995, 9:1473-1481.
11. Leppert D., Waubant E., Galardy R., Bunnett N.W., Hauser S.L. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995, 154:4379-4389.
12. Gao Q., Meijer M.J., Kubben F.J., Sier C.F., Kruidenier L., van Duijn W., et al. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 2005, 37:584-592.
13. Kirkegaard T., Hansen A., Bruun E., Brynskov J. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 2004, 53:701-709.
14. Pedersen G., Saermark T., Kirkegaard T., Brynskov J. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clin Exp Immunol 2009, 155:257-265.
15. Girard J.P., Springer T.A. High endothelial venules [HEVs]: specialized endothelium for lymphocyte migration. Immunol Today 1995, 16:449-457.
16. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
17. Nakamura S., Ohtani H., Watanabe Y., Fukuscima K., Matsumoto T., Kitano A., et al. In situ expression of the cell adhesion molecules in inflammatory bowel disease. Evidence of immunologic activation of vascular endothelial cells. Lab Invest 1993, 69:77-85.
18. Sandborn W.J., Feagan B.G., Rutgeerts P., Hanauer S., Colombel J.F., Sands B.E., et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013, 369:711-721.
19. Feagan B.G., Rutgeerts P., Sands B.E., Hanauer S., Colombel J.F., Sandborn W.J., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013, 369:699-710.
20. Bernstein C.N., Sargent M., Gallatin W.M. Βeta2-integrin/ICAM expression in Crohn's disease. Clin Immunol Immunopathol 1998, 86:147-160.
21. Van Assche G., Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel disease. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005, 288:G169-G174.
22. Jones S.C., Banks R.E., Haidar A., Gearing A.J., Hemingway I.K., Ibbotson S.H., et al. Adhesion molecules in inflammatory bowel disease. Gut 1995, 36:724-730.
23. Nielsen O.H., Langholz E., Hendel J., Brynskov J. Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in active inflammatory bowel disease. Dig Dis Sci 1994, 39:1918-1923.
24. Brown A.J. Regulation of vitamin D action. Nephrol Dial Transplant 1999, 14:11-16.
25. Cantorna M.T., Mahon B.D. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med 2004, 229:1136-1142.
26. Xue L.N., Xu K.Q., Zhang W., Wang Q., Wu J., Wang X.Y. Associations between vitamin D receptor polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis. Inflamm Bowel Dis 2013, 19:54-60.
27. Deluca H.F., Cantorna M.T. Vitamin D: its role and uses in immunology. FASEB J 2001, 15:2579-2585.
28. Cantorna M.T. Vitamin D, and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence?. Proc Soc Exp Biol Med 2000, 223:230-233.
29. Stio M., Treves C., Celli A., Tarantino O., d'Albasio G., Bagnoli S., et al. Synergistic inhibitory effect of cyclosporin A and vitamin D derivatives on T-lymphocyte proliferation in active ulcerative colitis. Am J Gastroenterol 2002, 97:680-689.
30. Stio M., Treves C., Martinesi M., d'Albasio G., Bagnoli S., Bonanomi A.G. Effect of anti-TNF therapy and vitamin D derivatives on the proliferation of peripheral blood mononuclear cells in Crohn's disease. Dig Dis Sci 2004, 49:328-335.
31. Martinesi M., Treves C., d'Albasio G., Bagnoli S., Bonanomi A.G., Stio M. Vitamin D derivatives induce apoptosis and downregulate ICAM-1 levels in peripheral blood mononuclear cells of inflammatory bowel disease patients. Inflamm Bowel Dis 2008, 14:597-604.
32. Martinesi M., Treves C., Bonanomi A.G., Milla M., Bagnoli S., Zuegel U., et al. Down-regulation of adhesion molecules and matrix metalloproteinases by ZK156979 in inflammatory bowel diseases. Clin Immunol 2010, 136:51-60.
33. 3 analogue with reduced hypercalcemic activity. J Invest Dermatol 2002, 119:1434-1442.
34. Nijenhuis T., van der Eerden B.C.J., Zügel U., Steinmeyer A., Weinans H., Hoenderop J.G., et al. The novel vitamin D analog ZK 191784 as an intestine-specific vitamin D antagonist. FASEB J 2006, 20:2171-2173.
35. Strauch U.G., Obermeier F., Grunwald N., Dunger N., Rath, Schölmerich J., et al. Calcitriol analog ZK191784 ameliorates acute and chronic dextran sodium sulphate-induced colitis by modulation of intestinal dendritic cell numbers and phenotype. World J Gastroenterol 2007, 13:6529-6537.
36. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989, 24:2-6.
37. Mowat C., Cole A., Windsor A., Ahmad T., Arnott I., Driscoll R., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011, 60:571-607.
38. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
39. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
40. Ala A., Dhillon A.P., Hodgson H.J. Role of cell adhesion molecules in leukocyte recruitment in the liver and gut. Int J Exp Pathol 2003, 84:1-16.
41. Meijer M.J., Mieremet-Ooms M.A., van Duijn W., van der Zon A.M., Hanemaaijer R., Verheijen J.H., et al. Effect of anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:200-210.
42. Lees C.W., Zacharias W.J., Tremelling M., Noble C.L., Nimmo E.R., Tenesa A., et al. Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathways. PLoS Med 2008, 5:e239.
43. Uhmann A., Niemann H., Lammering B., Henkel C., Heß I., Rosenberger A., et al. Calcitriol inhibits hedgehog signaling and induces Vitamin D receptor signaling and differentiation in the patched mouse model of embryonal rhabdomyosarcoma. Sarcoma 2012, 2012:1-7.
44. Dormoy V., Béraud C., Lindner V., Coquard C., Barthelmebs M., Brasse D., et al. Vitamin D3 triggers antitumor activity through targeting hedgehog signaling in human renal cell carcinoma. Carcinogenesis 2012, 33:2084-2093.
45. Kofla-Dlubacz A., Matusiewicz M., Krystek-Korpacka M., Iwanczak B. Correlation of MMP-3 and MMP-9 with Crohn's disease activity in children. Dig Dis Sci 2012, 57:706-712.
46. Lakatos G., Hritz I., Varga M.Z., Juhász M., Miheller P., Cierny G., et al. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases. Dig Dis 2012, 30:289-295.
47. Castaneda F.E., Walia B., Vijay-Kumar M., Patel N.R., Roser S., Kolachala V.L., et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice; central role of epithelial-derived MMP. Gastroenterology 2005, 129:1991-2008.
48. Di Sebastiano P., di Mola F.F., Artese L., Rossi C., Mascetta G., Pernthaler H., et al. Beneficial effects of Batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis. Digestion 2001, 63:234-239.
49. Medina C., Videla S., Radomski A., Radomski M.W., Antolin M., Guarner F., et al. Increased activity and expression of matrix metalloproteinase-9 in rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol 2003, 284:G116-G122.
50. Naito Y., Takagi T., Kuroda M., Katada K., Ichikawa H., Kokura S., et al. An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice. Inflamm Res 2004, 53:462-468.
51. Yamada A., Uegaki A., Nakamura T., Ogawa K. ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res 2000, 49:144-146.
52. Naito Y., Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspects Med 2005, 26:379-390.